Lasalocid inhibits melanoma by down-regulating FOXM1 through PI3K/AKT and JNK/P38 MAPK pathways

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Melanoma presents a significant therapeutic challenge due to its aggressive nature and limited treatment options.
• Lasalocid, an ionophore antibiotic, has emerged as a potential anticancer agent, but its mechanism in melanoma remains largely unelucidated.

Purpose of the Study:

• To investigate the efficacy of lasalocid as a melanoma therapeutic agent.
• To elucidate the molecular mechanisms underlying lasalocid's anti-melanoma effects.

Main Methods:

• In vitro assays to assess melanoma cell proliferation, migration, invasion, cell cycle arrest, and apoptosis.
• Transcriptome sequencing and bioinformatics analysis to identify key regulatory genes.
• In vitro confirmation of signaling pathway involvement (PI3K/AKT, JNK/P38 MAPK).
• In vivo studies to evaluate lasalocid's efficacy and safety in inhibiting melanoma growth.

Main Results:

• Lasalocid significantly inhibited melanoma cell proliferation, migration, and invasion.
• Lasalocid induced cell cycle arrest and apoptosis in melanoma cells.
• FOXM1 was identified as a critical hub gene in lasalocid's anti-melanoma activity.
• Lasalocid modulated FOXM1 expression via the PI3K/AKT and JNK/P38 MAPK pathways.
• In vivo studies demonstrated effective melanoma growth inhibition with good safety.

Conclusions:

• Lasalocid exhibits significant potential as a therapeutic agent for melanoma.
• The study elucidates lasalocid's mechanism of action, involving FOXM1 regulation through PI3K/AKT and JNK/P38 MAPK pathways.